NEAL KLEIMAN to Fibrinolytic Agents
This is a "connection" page, showing publications NEAL KLEIMAN has written about Fibrinolytic Agents.
Connection Strength
1.786
-
Balancing hemostasis and thrombosis in interventional vascular medicine and surgery. Methodist Debakey Cardiovasc J. 2011 Oct-Dec; 7(4):19-23.
Score: 0.335
-
Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discussion. J Interv Cardiol. 2011 Apr; 24(2):119-36.
Score: 0.316
-
Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. Thromb Haemost. 2006 Mar; 95(3):441-6.
Score: 0.227
-
Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi. Am J Cardiovasc Drugs. 2022 May; 22(3):231-238.
Score: 0.168
-
Optimizing Management of Patients With Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: The Importance of Distinguishing Pre-Existing From New Onset Atrial Fibrillation. JACC Cardiovasc Interv. 2017 01 09; 10(1):101-103.
Score: 0.121
-
Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2013 Oct 03; 168(3):2510-7.
Score: 0.093
-
Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circ Cardiovasc Interv. 2011 Oct 01; 4(5):463-73.
Score: 0.084
-
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. J Thromb Thrombolysis. 2011 Feb; 31(2):146-53.
Score: 0.080
-
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv. 2010 May 01; 75(6):928-35.
Score: 0.076
-
Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol. 2010 Jan 12; 55(2):114-21.
Score: 0.074
-
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA. 2005 Nov 23; 294(20):2594-600.
Score: 0.056
-
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004 Jul 07; 292(1):45-54.
Score: 0.051
-
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 Feb 19; 289(7):853-63.
Score: 0.046
-
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009 Jan; 2(1):37-45.
Score: 0.017
-
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.
Score: 0.016
-
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv. 2007 Jan; 69(1):73-83.
Score: 0.015
-
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. Am Heart J. 2004 Jul; 148(1):62-71.
Score: 0.013